Figure 2 - uploaded by Toshiaki Saito
Content may be subject to copyright.
(a) Loupe image: the tumor deeply invaded the muscle layer of the cervix. HE stain. (b). Tumor had a complex papillary pattern with epithelial stratification. Hematoxylin and eosin stain, ×40. (c) Pleomorphic and macronucleated atypical cells were observed. Hematoxylin and eosin stain, ×100.
Source publication
Aim:
Serous carcinoma of the uterine cervix (USCC) is a very rare malignant tumor, while this histological subtype is common in the ovary, fallopian tube, uterine corpus and peritoneum. Because of its rarity, details of the clinicopathological features of USCC are largely unknown. We retrospectively analyzed the clinicopathological characteristics...
Context in source publication
Context 1
... 10 courses of chemotherapy. Bevacizumab was added to the chemotherapy on the ninth course. She is currently undergoing maintenance therapy with bevacizumab and remains free of relapse for 2 years and 2 months. Pathological findings and high-risk HPV status of five cases Microscopic findings were similar to OSC in morphology in all five cases (Fig. 2a-c). In the low-power field, all cases had a complex papillary pattern and tufting with cellular buds. Nests of tumor cells invaded the cervical stroma in an irregular pattern, with clefts around the tumor cell nests. In the highpower field, pleomorphic and macronucleated atypical cells were seen. Case 3 had high-grade squamous ...
Similar publications
Background: We aimed to compare the clinical outcomes between intraperitoneal chemotherapy and dose-dense chemotherapy for the frontline treatment of advanced ovarian, fallopian tube and primary peritoneal cancer in women not receiving bevacizumab. Methods: All consecutive women with stage II~IV cancer treated with either frontline intraperitoneal...
Citations
... Serous carcinoma of endocervix previously thought to be separate subtype of adenocarcinoma of the cervix, is now recognized to be a variant of adenocarcinoma. 1 It is a rare variant with only a handful of cases reported worldwide. It is recognized to be a very aggressive tumour and usually presents in advanced stages. ...
... Serous carcinoma of the endocervix previously thought to be a separate subtype of adenocarcinoma of the cervix, is now recognized to be a variant of adenocarcinoma. 1 It is a rare variant with only a handful of cases reported worldwide. Serous carcinoma of the endocervix is known to have a bimodal age of presentation, while our patient was aged 57 years. ...
... Immunohistochemistry is used for differentiation of these tumours, previous reports have shown positivity for p53, p16 and CA 125. 1,3,6 These being rare variants with very less literature available worldwide, very little is known about their immunophenotyping. 8 Our case was negative for p53, p63 and p40, while CA 125 were raised. ...
Cervical cancers are the most common gynaecological cancers affecting women in India. Only rarely it is seen that cervical cancers metastasize to the ovaries. Serous carcinoma of cervix is a rare histological variant of adenocarcinoma of cervix, which is an aggressive tumour which usually presents in advanced stages and with metastasis to local and distant organs. Its abnormal and metastatic presentation disguising as ovarian malignancy often deceits the clinical and surgical decisions. Here we reported a rare presentation of primary endocervical cancer masquerading as ovarian carcinoma, which was treated with staging laparotomy followed by chemotherapy and patient had a good response with resolution of tumour masses.
... 7 Serous carcinoma shows positive expression of p53 and p16 through IHC. 1,8 Serous carcinoma of the ovary exhibits positive expression of WT-1 and ER, 9 while USCC typically displays weak or negative expression. 10 Napsin A and HNF-1β are frequently positive in clear carcinoma of the uterine cervix, ovary, and endometrium. 11 Gastric type is the most common subtype of cervical HPV-independent adenocarcinoma, and the markers of gastric type are frequently positive for MUC6, PAX8, CEA, CK7, and CK20, and negative for p16, ER, and PR. ...
On October 23, 2020, a 69‐year‐old Chinese female patient was admitted to Yuncheng Hospital due to a history of postmenopausal bleeding and lower abdominal pain for 5 months. The HPV test and pathology results indicated the presence of independent HPV in primary serous carcinoma of the uterine cervix. The genetic testing identified variants of uncertain significance (PAX8 p.Tyr 410 Ter and TP53 p.Asn 247 Ile), microsatellite instability stable (MSI‐S), tumor mutational burden (TMB) 7.33Muts/Mb, and an elevated tumor neoantigen burden. Before undergoing radical hysterectomy treatment, the patient exhibited a positive response to three cycles of intravenous docetaxel (100 mg/3 h) and carboplatin (450 mg/1 h). Following the surgery, she received an additional three cycles of docetaxel (100 mg/3 h) and carboplatin (500 mg/1 h), accompanied by 25 cycles of radiation therapy (DT 46Gy/2Gy/23f). Concurrently, cisplatin (450 mg/1 h) was administered. As of now, the patient has achieved 20 months of disease‐free survival.
... The tumor is characterized by >10 mitotic figures per 10 high-power fields. An intense acute and chronic inflammatory infiltrate is typically present within the cores of the papillae and in areas of stromal invasion [33]. Pleomorphic and macronucleated atypical cells are observed [32]. ...
... The tumor cells in SCUC are positive for p16, focally positive for p53 and ER, and negative for progesteron receptor. Age <65 years, stage >I, tumor size >2 cm, tumor invasion >10 mm, the presence of lymph node metastases, and elevation of serum CA-125 were associated with a poor prognosis [33]. Important for the DD between endometrial and endocervical carcinoma is the study which notes that p16 reactivity is mainly limited to areas with endometrioid or nonspecific cell type differentiation and does not occur in areas with normal endocervical mucinous morphology [34]. ...
We present a clinical case of a rarely diagnosed serous endometrial carcinoma (SEC) with infiltration of the cervix, left parametrium, right fallopian tube, with bilateral ovarian metastases and tumor cells in the peritoneal lavage. After extensive pathohistological and immunohistochemical examinatoin, it was proved to be a locally advanced serous endometrial carcinoma-pT3b N0 M0. The publication discusses the importance of immunohistochemical (IHC) differential diagnosis for determining the histogenesis of papillary serous adenocarcinoma. The main pathohistological dilemma is the determination of the histological subtype of this locally aggressive endometrial carcinoma. Another problem is the definition of the primary origin of the tumor, due to the difference between the pathohistological classification in cervical, uterine and tubo-ovarian adenocarcinomas, as well as the radically different postoperative adjuvant treatment. Incorrect differential diagnosis leads to misdefinition of the necessary complex oncological treatment.
... Other studies have reported high-risk HPV DNA in 0%-75% of cases. [6,[17][18][19] In the present study, two (29%) cases were of positive HPV DNA (type 18), which supports a weak association with SACC development. Further studies are needed to investigate the association between HPV infection and the occurrence of SACC. ...
... [14] Because of its rarity, the optimal primary management of SACC has not been determined. For early-stage SACC, preferred treatment options include radical hysterectomy, radiotherapy alone, [19,20] or primary surgery followed, depending on risk factors, by postoperative radiotherapy. [10,14] However, most cases are diagnosed with advanced-stage disease with metastases and require debulking surgery followed by combination chemotherapy [10,21] or radiotherapy. ...
Background:
Serous adenocarcinoma of the uterine cervix is an extremely rare variant of cervical adenocarcinoma. This study aimed to evaluate the clinicopathological and molecular features and outcomes of serous adenocarcinoma of the uterine cervix (SACC).
Materials and methods:
This was a retrospective study conducted based on the clinical and pathological data of seven patients diagnosed with SACC after hysterectomy, who were evaluated at the gynecologic oncologic centers between 2010 and 2019.
Results:
Five cases were diagnosed at Stage IB and two at Stage IV. All patients underwent radical hysterectomy with bilateral salpingo-oophorectomy and subsequently received postoperative radiotherapy or chemotherapy. One patient showed persistent disease, and two patients suffered recurrence. Immunohistochemical study showed that three (43%) of the seven patients were positive for p53, and among these three patients, two with diffuse strong p53 expression experienced an aggressive course with recurrences at pelvic lymph nodes, lung, and brain.
Conclusion:
High p53 expression and advanced stage may be associated with poorer clinical outcomes in SACC, which suggest that immunohistochemistry may contribute to the prediction of prognosis.
Cervical clear cell carcinoma (CCCC) is rare. This report describes the case of CCCC with a serous component. A 22-year-old woman presented with vaginal bleeding. A cervical tumor was discovered: pelvic magnetic resonance imaging revealed a tumor measuring 46 mm. Radical hysterectomy was performed based on the diagnosis of stage IB2 cervical cancer. After histological examination of the specimen revealed a coexisting invasive clear cell carcinoma (95%) and serous carcinoma (5%), five cycles of nedaplatin and irinotecan therapy were administered as postoperative adjuvant chemotherapy. Local recurrence in the vaginal vault was observed at 7 months after surgery. Radiation therapy and chemotherapy were administered. The patient is alive without evidence of recurrence at 26 months after surgery.
Background: The diagnostic role of Wilms’ tumor 1 (WT1) is well known in gynaeco-pathological setting, since it is considered a specific marker of serous histotype and adnexal origin. Moreover, its oncogenic role has been recently highlighted in many cancers and it has also been regarded as a promising target antigen for cancer immunotherapy. However, the relationship between its expression and prognostic role in uterine cancer remains unclear. We analyzed the diagnostic and prognostic role of WT1 expression in patients with uterine carcinoma by completing a search using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the PICOS (Participants, Intervention, Comparison, Outcomes, Study Design) model through PubMed, Scopus and Web of Science databases to identify studies that fit our search criteria. The objective of the current meta-analysis was to investigate the diagnostic and prognostic role of WT1 expression in patients with uterine carcinoma. Materials and Methods: A literature search was performed of the PubMed, Scopus, and Web of Science databases for English-language studies published from January 2000 to April 2020. Studies were considered eligible if they evaluated the WT1 expression in uterine carcinoma. Results: In total, 35 articles were identified that used uterine carcinoma criteria and provided data for 1616 patients. The overall rate of WT1 expression in uterine carcinoma was 25%. The subgroup analysis of uterine cancer types revealed that WT1 was expressed differently among different histotypes (endometrioid, clear cell, serous carcinoma and carcinosarcoma). Discussion and Conclusions: The WT1 immunohistochemical expression is not limited to serous histotype and/or ovarian origin. In fact, a significant proportion of endometrial adenocarcinomas can also show WT1 immunoreactivity. Moreover, our study suggests that WT1 may be a potential marker to predict the prognosis of patients with uterine cancer, but more studies are needed to confirm its role in clinical practice.
